Key Highlights and Investment Rationale
Good show on operational parameters: MPL reported healthy 15% YoY sales volume growth at 11,378MT. Further, NSR improved by 6.3% YoY Rs211/Kg. Net sales was up by 22.3% YoY to Rs2,406mn, while EBITDA came in at Rs468mn, up by 31% YoY. EBITDA margin expanded by 129bps over Q1FY25 to 19.4%. The company reported net profit of Rs216mn, higher by 30.5% YoY. In volume terms IML/Non-IML mix was at 75%/25%. Revenue from the Paints segment stood at Rs1050mn led by volume growth of 21.4% YoY at 5,593MT. The management cited the significant improvement in Paints segment due to incremental volume from Aditya Birla Group.
Encouraging revival in earnings, BUY with a TP of Rs906: After a subdued performance in last few quarters, MPL has come back stronger and registered healthy volume growth. We maintain positive outlook on the company and believe continued focus on capacity expansion, foray into high margin Pharma segment would pave the way for future earnings growth. BUY with a TP of Rs906.
